New cell therapy targets EBV-Linked cancers in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able to understand and voluntarily sign written informed consent. 2. Age 18 to 75 years, inclusive. 3. HLA genotype matches at least one of the following: HLA-A02:01, HLA-A11:01, or HLA-A\*24:02. 4. Karnofsky Performance Status (KPS) ≥ 70. 5. Life expectancy ≥ 3 months. 6. Diagnosed with EBV-associated lymphoproliferative disorders, including: 7. EBV infection-associated post-transplant lymphoproliferative disorder (PTLD) that is relapsed/refractory after at least first-line standard therapy; or 8. EBV-associated lymphoma confirmed by histology and/or cytology with EBER positivity (ISH/FISH), with no standard treatment available or not suitable for standard therapy, including but not limited to: EBV-positive DLBCL, EBV-positive NK/T-cell lymphoma, EBV-positive Hodgkin lymphoma, EBV-positive Burkitt lymphoma, EBV-positive nodal TFH lymphoma (AITL type), and EBV-positive primary cutaneous T-cell lymphoma, meeting protocol-defined relapsed/refractory criteria. 9. Absolute lymphocyte count ≥ 0.8 × 10\^9/L (except for PTLD participants). 10. Adequate organ and bone marrow function per protocol-defined criteria. 11. Participants of childbearing potential agree to use highly effective contraception throughout the study; women of childbearing potential must have a negative pregnancy test at screening. Exclusion Criteria: 1. Known hypersensitivity to the investigational product or its components. 2. Uncontrolled active graft-versus-host disease (GVHD) in PTLD participants. 3. Known primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgE syndrome). 4. Severe uncontrolled medical conditions that, in the investigator's judgment, make the participant unsuitable for enrollment. 5. Serious cardiac disease within 6 months prior to first infusion (e.g., myocardial infarction, severe/unstable angina, bypass surgery, NYHA class III-IV heart failure). 6. Chronic diseases requiring systemic immunosuppressants or systemic steroids (except local/inhaled steroids or physiologic replacement therapy). 7. History of other malignancy within the past 5 years, except carcinoma in situ (e.g., cervix, bladder, breast) or non-melanoma skin cancer. 8. Receipt of lymphocyte-based immunotherapy (e.g., CIK, DC, DC-CIK, LAK) within 3 months prior to consent. 9. Receipt of interferon or other targeted immunodeficiency drugs within 3 months prior to consent; prior high-dose IL-2 therapy. 10. Anti-cancer therapy within 14 days prior to consent (including chemotherapy or immunosuppressants/steroids); other cell therapy or live vaccines/attenuated vaccines or other investigational drugs within 28 days prior to consent; curative radiotherapy or major surgery within 4 weeks, or palliative local radiotherapy within 2 weeks prior to consent. 11. Prior immune therapy-associated ≥ Grade 3 immune-related adverse events (irAEs). 12. Unresolved toxicity from prior therapy \> Grade 1 (except alopecia any grade; peripheral sensory neuropathy ≤ Grade 2). 13. Uncontrolled psychiatric or neurologic disorders; drug abuse or alcohol dependence. 14. Positive HIV antibody; positive Treponema pallidum antibody; active hepatitis B (HBsAg and/or HBeAg positive with HBV-DNA above ULN) or active hepatitis C (HCV-Ab positive and HCV-RNA positive). 15. Uncontrolled severe active infection or contagious disease (excluding EBV infection). 16. Pregnant or breastfeeding women.